IdentifySensors Biologics has initiated the FDA pre-EUA (Emergency Use Authorization) submission for its rapid Ebola test, marking a pivotal step in the commercialization of its Check4 digital diagnostics platform. This innovative system is the first of its kind to use nanomaterials embedded on an electronic semiconductor to detect the Ebola virus. The platform digitizes molecular diagnostics by identifying electrical reactions from DNA and RNA—providing lab-quality accuracy at the point of care. This breakthrough merges biotechnology with electronics, opening the door to rapid, scalable disease detection on a global scale.

The Check4 device is a compact, Bluetooth-enabled diagnostic tool designed for real-time use in virtually any setting. Unlike conventional molecular tests that require laboratory infrastructure and skilled technicians, Check4 delivers fast results without the need for specialized personnel or facilities. It enables cloud connectivity, automated data capture, and even geolocation mapping—features that make it ideal for managing outbreaks, tracking disease spread, and improving accessibility in underserved areas. Its cost-efficiency and ease of use position it as a disruptive tool in global health, particularly in remote or emergency scenarios.